Mydecine Innovations Group Inc. Stock NEO Exchange
Equities
MYCO
CA62849F2008
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.175 CAD | +45.83% |
|
+29.63% | -61.11% |
Sales 2022 | - | Sales 2023 | - | Capitalization | 1.04M 758K |
---|---|---|---|---|---|
Net income 2022 | -11M -8.04M | Net income 2023 | -20M -14.61M | EV / Sales 2022 | - |
Net Debt 2022 | 153K 112K | Net Debt 2023 | 5.39M 3.93M | EV / Sales 2023 | - |
P/E ratio 2022 |
-0.44
x | P/E ratio 2023 |
-0.03
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.04% |
1 day | +45.83% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Roscow
FOU | Founder | - | 13-09-26 |
Damon Michaels
FOU | Founder | - | 13-09-26 |
David Bartch
CEO | Chief Executive Officer | - | 18-06-21 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Bartch
CEO | Chief Executive Officer | - | 18-06-21 |
Damon Michaels
FOU | Founder | - | 13-09-26 |
Robert Roscow
FOU | Founder | - | 13-09-26 |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+22.15% | 46.56B | |
+45.38% | 41.67B | |
-2.37% | 41.16B | |
+33.84% | 32.4B | |
-6.35% | 28.1B | |
+20.42% | 28.18B | |
+48.83% | 14.52B | |
+45.00% | 13.74B | |
+0.06% | 12.17B |
- Stock Market
- Equities
- MYCOF Stock
- MYCO Stock